Viveve Medical (NASDAQ:VIVE) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Viveve Medical to post earnings of ($0.18) per share for the quarter.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. Viveve Medical had a negative net margin of 265.51% and a negative return on equity of 2,979.48%. The company had revenue of $3.01 million for the quarter, compared to the consensus estimate of $2.98 million. On average, analysts expect Viveve Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ VIVE remained flat at $$0.15 on Wednesday. 1,250,339 shares of the company’s stock traded hands, compared to its average volume of 5,299,871. Viveve Medical has a 12 month low of $0.14 and a 12 month high of $3.71. The company has a market cap of $7.22 million, a PE ratio of -0.09 and a beta of -0.21. The company has a debt-to-equity ratio of 6.21, a quick ratio of 3.43 and a current ratio of 3.95. The stock has a 50-day moving average price of $0.32.
A number of research firms have recently weighed in on VIVE. Stifel Nicolaus lowered shares of Viveve Medical from a “buy” rating to a “hold” rating and cut their price objective for the company from $3.00 to $1.00 in a research report on Monday, July 22nd. LADENBURG THALM/SH SH lowered shares of Viveve Medical from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th. Mizuho lowered shares of Viveve Medical from a “buy” rating to an “underperform” rating and cut their price objective for the company from $4.00 to $0.20 in a research report on Tuesday, July 23rd. Maxim Group lowered shares of Viveve Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Raymond James lowered shares of Viveve Medical from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $2.24.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
Featured Story: Cost of Goods Sold (COGS)
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.